Index

abdominal massage, 220
acetaminophen, for PLP, 162
acetylcholine, 81
achalasia, 58
active exercise, for spasticity, 122–3
active rehabilitation, 5
activities of daily living (ADL), 4
instrumental, 76–9
Activity Card Sort, 42
activity co-ordinators, 5
acupuncture, 146
clinical trials on, 64
for hyposalivation, 62–3
for xerostomia, 62–3
AD. See autonomic dysreflexia
adaptation exercises, 93–4
in vestibular rehabilitation, 94–6
adaptive interventions, 7
adjustment disorders, 22–3
factors affecting, 23
pharmacological management of, 22–3
symptoms of, 22
treatment, 22–3
ADL. See activities of daily living
aging, dysphagia and, 52–3
AIE. See anoxic-ischemic encephalopathy
alpha blockers, 209
ALS, 57
incidence of, 62–3
alternating attention, 13
Alzheimer’s dementia, 107–8
amantadine, 45
for DOC, 36–8
evidence, 36–8
indication for, 36–8
for Parkinson’s disease, 140
rational for, 36–8
side effects of, 36–8
ambulatory blood pressure measurements, in AD, 197
anomia, 14
anoxic-ischemic encephalopathy (AIE), 32
antegrade irrigation surgery, 220–1
anticholinergic medications
contraindications for, 70
for hypersalivation, 69
for Parkinson’s disease, 140
anticonvulsants, for PLP, 163
antidepressants, 23
effects of, 24–5
for PLP, 162–3
side effects of, 25
antihistamines, 62–3
antipsychotics, 26, 28, 62–3
anxiety disorders, 25–6
meta-analysis of studies on, 25
MS and, 25
Parkinson’s disease and, 25
pharmacologic management of, 26
SSRIs for, 26
stroke and, 25
walking and, 108
anxiolytics, 23
AOS. See apraxia of speech
aphasia, 31
anomia, 14
chronic, 43, 46–7
Cochrane review on, 42
conduction, 14
global, 14
pharmacological interventions for, 44–5
rTMS for, 43–4
tDCS for, 44
apomorphine, 139
for Parkinson’s disease, 142
applied relaxation, 25–6
apraxia of speech (AOS), 41, 44
APT. See Attention Processing Training
ARAS. See ascending reticular activating system
awal, 30
artificial urinary sphincter (AUS), 212–13
ascending reticular activating system
(ARAS), 32
aspiration, 57
assessments, in neurorehabilitation, 1
atropine, 63
action of, 68
for hypersalivation, 68–9
attention
alternating, 13
divided, 13
evidence-based cognitive rehabilitation for, 13
focused, 13
impairment of, 13
selective, 13
sustained, 13
Attention Processing Training (APT), 196–7
augmentation cystoplasty, for LUT, 211–12
augmented feedback, for upper limb impairment, 79
augmenting interventions, 6
AUS. See artificial urinary sphincter
autonomic dysreflexia (AD), 196–7
ambulatory blood pressure measurements, 197
boosting, 198
causes of, 197
procedures causing, 197
signs of, 197
treatment of, 197
baclofen, 126
intrathecal, 38, 81, 129–30
for spasticity, 125
balance, 105–7
walking and, 113
barbecue rotation, 101
baroreflex, 186
Barthel index, 4
basal ganglia, 107
BDNF. See Brain Derived Neurotrophic Factor
Beck Anxiety Inventory, 25
behavioural disorders, 22
behavioural modifications, for hypersalivation, 66
behavioural therapy, toileting and, 207
Benign Paroxysmal Positional Vertigo (BPPV), 30
defining, 90
evidence-base for, 100–1
horizontal canal, 101
posterior canal, 100
posterior semicircular canal, 90
repositioning manoeuvres for, 91, 100–1
benzodiazepines, 23, 26, 28
for spasticity, 127
beta-blockers, 28, 62–3
bifemelane, 45
biofeedback, 6
for dysphagia, 56–7
for neurogenic bowel dysfunction, 220
for PLP, 162
for upper limb impairment, 79
biomarkers, 47
biomedical engineers, 5
bipedal standing, 105
bipolar disorder, MS and, 26
bladder outlet dysfunction, 212
blood pressure regulation, 188
Bobath approach, for upper limb impairment, 79
Bobath’s neurodevelopmental approach, 6–7
body scan, 18
body schema concept, 159
botulinum toxin (BoNT), 58, 63, 81
for dysphagia, 58
for hypersalivation, 67–8
for LUT, 210–11
in neuropathic pain, 154–5
for Parkinson’s disease, 140
for spasticity, 128–9
BPPV. See Benign Paroxysmal Positional Vertigo
brachytherapy, 58
Braden Scale, 180
Brain Derived Neurotrophic Factor (BDNF), 75–6
brain mapping, 43
brain-machine interfaces, for upper limb impairment, 81–2
Brief Pain Inventory, 160
Brindley stimulator, 213
Broca’s area, 44
bromocriptine, 38, 45
Brunnstrom’s technique, 6–7
BVH. See vestibular hypofunction
Calcitonin, 163
calcium channel blockers, 58, 147–9, 150
 cannabinoids, 153
for spasticity, 127–8
 carbamazepine, 28
carboxymethylcellulose (CMC), 64
cardiovascular training, for walking disorders, 112
carotid sinus stimulation, 194
catheterization, 207–8
counselling, 233
indwelling, 208
Cawthorne-Cooksey exercises, 93
CBD. See Corticobasal Degeneration
CBT. See cognitive behavioural therapy
central pattern generators (CPGs), 105–7
cerebellum, in walking, 107
cervical osteophytectomy, 58
cevimeline
for hyposalivation, 66
for xerostomia, 66
challenging behaviour, 27–8
boundaries in, 27
clinician response to, 27
debriefing, 28
personal space and, 27
underlying causes of, 28
verbal contact in, 27
verbal de-escalation in, 28
chemical myotomy, 58
chemical neurolysis, for spasticity, 128–9
chewing gum, 64
cholinergic drugs, for speech-language pathology, 45
chronic aphasia, 43, 46–7
CIMT. See Constraint Induced Movement Therapy
clonazepam, 126
clonus, 119
clozapine, 62–3
CMC. See carboxymethylcellulose
Cochrane review, 24, 28, 64, 171
on aphasia, 42
cognitive behavioural therapy (CBT), 16, 24, 146
defining, 24
focus of, 24
for insomnia, 17
manualized, 17
model of, 24
modifications, 17
for pain, 19
for PLP, 162
for PLP and PLP, 162
cognitive functioning, 10
coma, 30
communication, evidence-based cognitive rehabilitation for, 14–15
complimentary interventions, for upper limb impairment, 79
COMT inhibitors, for Parkinson’s disease, 140
conduction aphasia, 14
Constant Therapy, 47
Constraint Induced Language Therapy, 42–3
Constraint Induced Movement Therapy (CIMT), 6
for upper limb impairment, 79
construc validity, 4
content validity, 4
contingency plans, 3, 23
conus medullaris, 203
cortical areas, in walking, 107
Corticobasal Degeneration (CBD), 134
couple therapy, 233
CPGs. See central pattern generators
cranial nerves, 61
Crede manoeuvre, 207
depression
in Parkinson’s disease, 24, 140
rates of, 23
for DOC, 38
default mode network (DMN), 32
deficit mode network (DMN), 32
dementia with Lewy Bodies (DLB), 168–9
reading and, 167–8
deep brain stimulation (DBS), 115–16
for DOC, 38
default mode network (DMN), 32
Dementia with Lewy Bodies (DLB), 168–9
depression
in Parkinson’s disease, 24, 140
rates of, 23–4
stroke and, 80–1
detrusor overactivity (DO), 206
detrusor-sphincter dysynergia (DSD), 212
dextroamphetamine, 45
diabetic peripheral neuropathy, 108, 153–4
Diagnostic and Statistical Manual of Mental Disorders (DSM-V), 22
diazepam, 26
dieticians, 5
in Parkinson’s disease, 136, 139
diplopia, 99, 172
driving and, 173
general participation and, 172
reading and, 172
discriminant validity, 4

disorders of consciousness (DOC), 30
amantadine for, 36–8
clinical spectrum of, 30–1
as continuum, 30–1
DBS for, 38
dopaminergic drugs for, 38
intrathecal baclofen for, 38
modafinil for, 38
neuroanatomy in, 32
non-pharmacological treatment, 32–6
pathophysiology of, 32
pharmacological treatment, 36–8
surgical treatment for, 38
verticalization to near standing position for, 32–4
zolpidem for, 37
divided attention, 13
dizziness, 90
visually induced, 94
Dizziness Handicap Inventory, 93
DLB. See Dementia with Lewy Bodies
D-Mannose, 205
DMN. See default mode network
DOC. See disorders of consciousness
donepezil, 45
dopamine, 24–5
dopamine agonists, for Parkinson’s disease, 139
dopaminergic drugs for DOC, 38
for speech-language pathology, 45
dorsal root entry zone (DREZ), 154
driving
decreased visual acuity and, 169–70
diplopia and, 173
hemianopia and, 172
nystagmus and, 174
visual impairment and, 167
DSD. See detrusor-sphincter dysynergia
DSM-V. See Diagnostic and Statistical Manual of Mental Disorders
dual task training, for walking disorders, 112
Duodopa, for Parkinson’s disease, 142
dysarthria, 43
dysautonomic crises, 198
dysphagia, 53, 62
aetiologies of, 52–3
aging and, 52–3
biofeedback for, 56–7
botulinum toxin for, 58
EMST for, 57
food consistency and, 54
general treatment of, 53–4
non-pharmacological treatment of, 54–8
pharmacological treatment of, 58
signs of, 53
surface electrical stimulation for, 57
surgical treatment, 58
ED. See erectile dysfunction
education, about spasticity, 120–2
electromagnetic stimulation, 35–6
rationale for, 35
electromechanical training, walking and, 113
electrostimulation
for hyposalivation, 64–5
for xerostomia, 64–5
Emory Ambulation Profile, 110
emotional dysregulation, 11
emotional functioning, psychological rehabilitation intervention for, 15–16
demotion incontinence, 26
EMST. See expiratory muscle strength training
enriched environments, 75–6
Epley manoeuvre, 100
equinus, 109
erection dysfunction (ED)
local therapy for, 229
oral treatment for, 228–9
pelvic floor physiotherapy, 229–30
penile prosthetic surgery for, 229
ERIGO®3, 33
EST. See explorative saccade training
European Stroke Scale, 81
EUS. See external urethral sphincter muscle
evidence-based cognitive rehabilitation
acquisition stage, 10–11
adaptation stage, 10–11
application stage, 10–11
for attention, 13
for communication, 14–15
for executive functioning, 10–11
for hemispatial neglect, 14
for language, 14–15
for memory, 12–13
problem-solving strategies, 12
executive functioning, evidence-based cognitive rehabilitation for, 10–11
exercise-related hypotension, 193
fluid replacement, 193
non-pharmacological measures, 193
exercises. See also specific exercises
adaptation, 93–6
fixation, 94–6
high intensity, 137
stroke and, 76
swallowing, 54–6
in vestibular rehabilitation, 95
expiratory muscle strength training (EMST), for dysphagia, 57
explorative saccade training (EST), 171
external urethral sphincter muscle (EUS), 212
extrapyramidal signs, in walking disorders, 114–15
face validity, 4
falls
medications associated with, 115
walking disorders and, 115
Familial Dysautonomia (FD), 198
dysautonomic crises, 198
pharmacological treatment of, 198–9
typical, 198
Familial Auditory Sensory Training (FAST), 34
family, in neurorehabilitation, 3
fatigue
psychological rehabilitation intervention for, 18
self-reported, 18
FD. See Familial Dysautonomia
fear, walking and, 108
FEES. See fibre-optic endoscopic evaluation of swallowing
FES. See functional electrical stimulation
FGG. See fibroblast growth factor
fibre-optic endoscopic evaluation of swallowing (FEES), 53
fibroblast growth factor (FGF), 81
fixation exercises, 94–6
fluid intake control, 208
fluoxetine, 80
fluvoxamine, 45
focused attention, 13
food consistency, 54
Fugl-Meyer Scale, 75, 76, 80, 81
functional electrical stimulation (FES), 33
for spasticity, 124
for upper limb impairment, 79
for walking disorders, 111
functional independence measure, 4
functional neurosurgery, for walking disorders, 115–16
functional walking disorders, 108
GABA agonists, 37
gabapentin, 80
for spasticity, 127
Gabapentin, 126
GAD-7. See Generalized Anxiety Disorder 7
gait. See walking
galantamine, 45
gaze transfer, 94
GDNF. See glial cell derived neurotrophic factor
general participation
decreased visual acuity and, 168–9
diplopia and, 172
hemianopia and, 171–2
nystagmus and, 173–4
visual impairment and, 166–7
Generalized Anxiety Disorder 7 (GAD-7), 25
generic VR booklet, 93
gentamicin, 92
Ghent Participation Scale, 4
GIST. See Group Interactive Structured Treatment
Glasgow coma scale, 4
glaucoma, 65
glial cell derived neurotrophic factor (GDNF), 81
global aphasia, 14
globus pallidus internus (GPI), 37
glycopyrrolate, 63
adverse effects of, 70
for hypersalivation, 69–71
goal planning
decision making and, 2
impairments and, 2–3
negotiation in, 2
neurorehabilitation, 1
GPI. See globus pallidus internus
grief, 25
Group Interactive Structured Treatment (GIST), 15
Gufoni manoeuvre, 101
heads, in TBI, 18–19
HEC. See hydroxyethylcellulose
hemianopia, 170
driving and, 172
general participation and, 171–2
reading and, 170–1
hemispatial neglect, evidence-based cognitive rehabilitation for, 14
high intensity exercise (HIT), 137
hormonal replacement therapy (HRT), 230
Hospital Anxiety and Depression Scale, 4, 25
HPMC. See hydroxypropylmethylcellulose
HRT. See hormonal replacement therapy
hydration, 52
hydroxyethylcellulose (HEC), 64
hydroxypropylmethylcellulose (HPMC), 64
hypersalivation
anticholinergic medications for, 69
atropine for, 68–9
behavioural modifications for, 66
defining, 62
glycopyrrolate for, 69–71
radiotherapy for, 66–7
scopolamine for, 69
surgical treatment of, 71
treatment for, 63
hypersensitivity, 194
hypertension
pharmacological treatment of, 196
treatment of, 196
hypertensive vomiting attacks, 198
hypertonia, 119–20
hyposalivation, 61, 64
acupuncture for, 62–3
cevimeline for, 66
defining, 62
electrostimulation for, 64–5
pharmacological treatments for, 65
pilocarpine for, 65–6
topical preparations for, 63–4
treatment for, 63
hypotension, exercise-related, 193
IADLs. See instrumental activities of daily living
ICD-10. See International Statistical Classification of Diseases and Related Health Problems
ICF. See International Classification of Function
Impact on Participation and Autonomy Questionnaire, 4
impairment, 1
of attention, 13
goal planning and, 2–3
scales, 4
indwelling catheters, 208
infection control, pressure ulcers, 183
inshoe orthoses, 112
insomnia, CBT for, 17
instrumental activities of daily living (IADLs), upper limb impairment and, 76–9
intercourse-outercourse approach, 232–3
interdisciplinary team models, 5
International Classification of Function (ICF), 1, 42
International Statistical Classification of Diseases and Related Health Problems (ICD-10), 22, 25
internet-based VR, 93
interpersonal therapy (IPT), 24
model of, 25
Inter-Rater reliability, 4
interventions
adaptive, 7
augmenting, 6
neurorehabilitation, 4–5
priming, 5–6
restorative, 5
specific, 6–7
intranuclear baclofen
for DOC, 38
for upper limb impairment, 81
intrathecal therapies, for spasticity, 129
IPT. See interpersonal therapy
IRT. See item response theory
ischemic penumbra, 46
item response theory (IRT), 4
JFK Coma Recovery Scale – Revised (CRS-R), 31, 33
kinesia, 134
lamotrigine, 151
language, evidence-based cognitive rehabilitation for, 14–15
laryngectomy, 58
larynx, 52
laxatives, for neurogenic bowel dysfunction, 220
levodopa, 38, 45
for Parkinson’s disease, 139–41
for stroke, 80
Lidocaine, 163
life goals, 2–3
Life Participation Approach to Aphasia (LPAA), 42
lip-reading, 46
LIS. See locked-in syndrome
lithium, 26
locked-in syndrome (LIS), 31–2
long-term neurologic conditions, salivary disorders and, 62–3
lorazepam, 26
lower urinary tract (LUT), 202
augmentation cystoplasty for, 211–12
BoNT for, 210–11
conservative treatment of, 208–9
holistic evaluation of patient in, 203–4
long-term follow-up, 213–14
mirabegron for, 210
oxybutynin for, 209
parasympatholytic drugs for, 209
propiverine hydrochloride for, 209–10
solifenacin for, 210
tibial nerve stimulation for, 211
tolterodine for, 210
treatment aims, 202–3, 206
trospium for, 210
Index

lower urinary tract dysfunction, 202
LPAA. See Life Participation Approach to Aphasia
lubricants, for sexual dysfunction, 231
LUT. See lower urinary tract
MAO-B inhibitors, for Parkinson’s disease, 139
Masako manoeuvre, 56
Maudsley Prescribing Guidelines in Psychiatry, 28
MBSR. See mindfulness based stress reduction protocol
McGill pain questionnaire (MPQ), 160
MCS. See minimally conscious state
MDC. See minimum detectable change
MDR. See multi-drug resistance
Medical Research Council (MRC), 4
meditation, 18
Melodic Intonation Therapy, 46
memantine, 45
memory
evidence-based cognitive rehabilitation for, 12–13
external aids, 12–13
notebooks, 12–13
working, 13
Mendelsohn manoeuvre, 54–6
Ménière’s disease, 92, 100
mental practice, for upper limb impairment, 79
metacognitive training, 12
methylprednisolone, 92
MI. See motivational interviewing
micturition, 209
Mindful Intention therapy protocol (MBSR), 18
mindfulness-based cognitive therapy, 19
minimally conscious state (MCS), 30, 33
emergence from, 30–1
minimum detectable change (MDC), 110
mirabegron, for LUT, 210
mirror therapy for PLP, 162
for upper limb impairment, 79
MMIT. See Modified Melodic Intonation Therapy
modafinil, DOC for, 38
Modified Ashworth scale, 4
Modified Melodic Intonation Therapy (MMIT), 46
Modified Rankin Scale, 76
modified self-Epley, 91
moisturizing gels, 64
molecular drug targets (TRPV), 147–9
for neuropathic pain, 150–1
mono-synaptic stretch reflexes, 107
mood disorders, 22
mood stabilisers, 26
motivation, upper limb impairment treatment and, 75
motivational interviewing (MI), 16
executing stage, 16
focusing stage, 16
initial phase, 16
maintenance stage, 16
motor skill learning, 76
movement, in Parkinson’s disease, 137
MPQ. See McGill pain questionnaire
MRC. See Medical Research Council
MS. See multiple sclerosis
MST. See Multiple System Atrophy
M2/3. See Multi-linked Musculoskeletal System
Music and Movement Therapy, 146
music therapy
indication for, 34
rationale, 34
review of evidence, 34–5
for speech-language pathology, 46
for upper limb impairment, 79
Music Upper Limb Therapy-Integrated multidisciplinary team models, 5
for Parkinson’s disease, 135
multi-drug resistance (MDR), 204
multi-linked musculoskeletal system, in walking, 108
multiple sclerosis (MS)
anxiety disorders and, 25
bipolar disorder and, 26
suicide and, 26–7
Multiple System Atrophy (MSA), 134, 186
negative thoughts, 24
neuroanatomy, in DOC, 32
neurogenic bowel dysfunction, 218
biofeedback for, 220
general treatment, 218–19
laxatives for, 220
non-pharmacological treatment of, 219–20
prokinetics for, 220
suppositories for, 220
neurological impairment, defining, 1
neuromodulation, 220–1
neuropathic pain
aetiology of, 144
botulinum toxin in, 154–5
defining, 144
diagnosis of, 145
interventional therapy for, 153–4
non-pharmacologic therapy for, 145–6
opioid analgesics for, 152–3
pharmacologic therapy, 146–50

SNRIs for, 150
sodium channel antagonists for, 151–2
tramadol for, 152–3
tricyclic antidepressants for, 150
TRPV, 150–1
neuropeptides, 75–6
neuropsychological approaches, 6–7
neuropsychological assessment, 11
neuropsychologist, 5
neurorehabilitation assessment in, 1
family in, 3–4
goal planning, 1
interventions, 4–5
outcome measurement, 4
post-acute, 15
team members, 5
Nintendo Wii Fit Plus, 98–9
nitrates, 58
NMDA receptor antagonist, 163
nocturnal polyuria, 210
non-invasive brain stimulation, 43–4
nonpharmacological treatment, 160–1
nonsteroidal anti-inflammatory drugs (NSAIDs), for PLP, 162
noradrenaline, 24–5
noradrenergic based drugs, for speech-language pathology, 45
norepinephrine, 45
Northern Manhattan Stroke study, 75
Norton Scale, 180, 181
NSAIDs. See nonsteroidal anti-inflammatory drugs
nutrition, 52
nystagmus, 173
driving and, 174
general participation and, 173–4
reading and, 173
occupational therapist, 5, 10
occupational therapy, for Parkinson’s disease, 135–6, 138
oesophageal stents, 58
OH. See orthostatic hypotension
older adults, vestibular impairment in, 90
opioid analgesics, 147–9
for neuropathic pain, 152–3
for PLP, 163
organizational psychology, 3
Orientation Books, 12–13
ORLA-VT, 47
oropharynx, 25
orthopaedic management, of walking disorders, 115
orthostatic hypotension (OH), 187–8
activities to avoid in, 190
autonomic response and, 187
definition of, 187–8
non-pharmacological measures of, 190–1
pharmacological treatment of, 191–2
prevention, 191–2
symptoms of, 190
treatment of, 188–92
triggers of, 188
typical symptoms of, 188
orthotic devices, 7, 136
spasticity and, 124
for walking disorders, 112
orthotists, 5
oscillopsia, 99, 105–7
outcome measurement, 116
neurorehabilitation, 4
oxybutynin, for LUT, 209
oxytocin, 75–6
pain. See also neuropathic pain;
phantom limb pain
causes of, 18
CBT for, 19
psychological rehabilitation intervention for, 18–19
parasympatholytic drugs, for LUT, 209
Parkinson’s disease, 62–3, 111, 115–16, 134
aetiology of, 134
amantadine for, 140
anticholinergic medications for, 140
antitussive disorders and, 25
apomorphine for, 142
assessment, 138
atypical, 135
botulinum toxin for, 140
COMT inhibitors for, 140
depression in, 24, 140
disticators in, 136, 139
dopamine agonists for, 139
Duodopa for, 142
incidence of, 62–3
levodopa for, 139–41
MAO-B inhibitors for, 139
medication for, 135
medication side effects in, 141
motor fluctuations, 140
motor symptoms of, 134
movement in, 137
multidisciplinary team models for, 135
non-motor symptoms of, 134–5
non-pharmacological treatment, 136
occupational therapy for, 135–6, 138
pharmacological treatment, 139–41
physiotherapy, 135–6, 137–8
speech-language therapy in, 136, 138–9
swallowing in, 136
transfers in, 138
Parkinson’s disease nurse specialist
parotid gland, 61, 71
paroxysmal sympathetic storm/ hyperactivity (PSH), 196
medications used for, 196
passive movements, spasticity and, 123
pathophysiology, of DOC, 32
PDNS. See Parkinson’s disease nurse specialist
PE. See premature ejeculation
pedunculopontine nucleus (PPN), 107
PEG. See percutaneous gastrostomy tube
PEJ. See percutaneous jejunostomy tube
pelvic floor physiotherapy, 229–30
pelvic muscle floor training (PFMT), 206
penile prosthetic surgery, 229
percutaneous gastrostomy tube (PEG), 58
percutaneous jejunostomy tube (PEJ), 58
peripheral lesions, 203
personal space, challenging behaviour and, 27
PFMT. See pelvic muscle floor training
PGM. See polyglyceryl methacrylate (PGM)
phantom limb pain (PLP), 158, 161
phantom limb sensation (PLS), 158
phenol, intrathecal, 130
phenol, intraskeletal, 130
phenol, intrathecal, 130–1
phantom limb sensation
phenol, intrathecal, 130–1
phobic postural vertigo, 108
physiotherapist, 5
piracetam, 45
PISST model, 228
PLP. See phantom limb pain
PLS. See phantom limb sensation
PNF. See proprioceptive neuromuscular facilitation
polyglyceryl methacrylate (PGM), 64
polyneuropathy, 146
polyuria, nocturnal, 210
postprandial hypotension (PPH), 192
non-pharmacological measures, 192
pharmacological measures, 192
post-traumatic stress disorder (PTSD), 16–17, 26
postural alignment, vestibular rehabilitation and, 95–6
postural changes, 53
postural control, 90
postural management, of spasticity, 122
postural tachycardia syndrome (PoTS), 195
non-pharmacological measurements, 195
PPH. See postprandial hypotension
PPN. See pedunculopontine nucleus
Practice Guidelines, 12
Practice Standards, 10, 12, 19
pregabalin, 80
for spasticity, 127
Pregabalin, 126
premature ejeculation (PE), 232
pressure ulcers, 178
aetiology, 178
category I, 180
category II, 180
category III, 180
category IV, 180
causes of, 178–9
classification of, 179
complications of, 181
healing, 180–1
infection control, 183
management of, 181–3
pressure relief, 181
prevention, 179
risk assessments, 180
risk factors, 179
support surfaces, 181–2
surgical intervention for, 183
wound debridement for, 183
wound dressings for, 183
wound healing for, 183
preventive rehabilitation, 5, 7
PRF. See pulsed radiofrequency
priming interventions, 5–6
ProACT, 213
progressive resisted exercise, 111
Progressive Supranuclear palsy (PSP), 134
prokinetics, for neurogenic bowel dysfunction, 220
Index

propiverine hydrochloride, for LUT, 209–10
proprioceptive neuromuscular facilitation (PNF), 6–7
proton pump inhibitors, 58
PSH. See paroxysmal sympathetic storm/hyperactivity
PSP. See Progressive Supranuclear palsy
psychiatrists, 136
psychopedagogy, 17–18
psychological rehabilitation intervention, 15
for emotional functioning, 15–16
for fatigue, 17–18
for pain, 18–19
for sleep, 16–18
psychologists, 136
psychometrics, 4
psychotherapy, 19
PTSD. See post-traumatic stress disorder
pulsed radiofrequency (PRF), 153
punch biopsy, 145
pusher syndrome, 107–8
radiotherapy
adverse effects of, 66–7
for hypersalivation, 66–7
rasagiline, 139
RASCAL analysis, 4
reading
decreased visual acuity and, 167–8
diplopia and, 172
hemianopia and, 170–1
lip-reading, 46
nystagmus and, 173
visual impairment and, 166
recovery, promotion of, 6
recumbent, 109
rehabilitation nurse, 5
rehabilitation physician, 5
relaxation, applied, 25–6
reliability
Inter-Rater, 4
Test-Retest, 4
reperfusion therapies, for upper limb impairment, 80–1
repetitive task training, for upper limb impairment, 79
repetitive transcranial magnetic stimulation (rTMS), 5–6
for aphasia, 43–4
responsiveness, 4
restorative interventions, 5
Rivermead Motor Assessment, 80
robotics
for upper limb impairment, 79
walking and, 113
role transitions, 25
Rood’s approach, 6–7
ropinirole, 139
rTMS. See repetitive transcranial magnetic stimulation
saccades, 95–5
saccadic substitution, 93–4
sacral neuromodulation (SNM), 211
SafesStraw, 54
saliva. See also hypersalivation;
hyposalivation control of, 61
flow rate, 61, 62
production, 61
stimulated, 61, 62
unstimulated, 61, 62
sialorrhea. See also hypersalivation;
spasms, 119
spasticity, 119
sodium channel antagonists, 147
for walking disorders, 112
inshoe orthoses, 112
diary, 17
psychological rehabilitation
hygiene, 17
rules, 17
TBI and, 16
triggers, 120
benzodiazepines for, 127
baclofen for, 125
gabapentin for, 127
botulinum toxin for, 128–9
for neuropathic pain, 150
serotonin-noradrenaline reuptake inhibitors (SNRI), 24–5
serotonin syndrome, 152–3
serotonin-noradrenaline reuptake inhibitors (SNRI), 24–5
for neuropathic pain, 150
serous cells, 61
sex therapy, 232
sexual activity planning, 230–1
sexual dysfunction, 224
clinical overview, 224–7
high level, 228, 231
level 2, 228
low level, 225, 228
medications for, 231
middle level, 225
psychological therapy for, 231–3
rehabilitation principles, 233–4
sensorimotor levels of, 226–7
treatments, 226–7, 228, 231
Shaker Exercise, 56
shared decision making, 2
shoes
inshoe orthoses, 112
sleep
diary, 17–18
for walking disorders, 112
TBI and, 16
social workers, 5
spasms, 119
trigger, 120
spasticity, 119
active exercise for, 122–3
assessment, 120
baclofen for, 125
benzodiazepines for, 127
botulinum toxin for, 128–9
cannabinoids for, 127–8
chemical neurolysis for, 128–9
dantihypertensive for, 127
education about, 120–2
FES for, 124
focal treatment of, 128
gabapentin for, 127
goal setting, 120
individualized treatment plan, 120
intrathecal therapies for, 129
| management algorithm, 121 |
| oral medication for, 125–8 |
| orthotic devices and, 124 |
| passive movements and, 123 |
| pathophysiology of, 119–20 |
| postural management of, 122 |
| pregabalin for, 127 |
| seating and, 123–4 |
| self-management, 120–2 |
| splinting and, 124 |
| standing and, 123 |
| stretching for, 123–4 |
| stroke |
| animal studies on, 75–6 |
| anxiety disorders and, 25 |
| disorders in, 47 |
| exercise and, 76 |
| spasticity and, 80 |
| treatment, 74–5 |
| upper limb impairment and, 74 |
| stump pain (SP), 158 |
| subcortical systems, in walking, 107 |
| sublingual gland, 61 |
| submandibular gland, 61 |
| transposition of, 71 |
| substance abuse, 15–16 |
| subthalamic nucleus (STN), 115–16 |
| suicide, 26–7 |
| deaths from, 26 |
| MS and, 26–7 |
| risk assessment, 27 |
| supine hypertension, 195 |
| non-pharmacological measurements, 195 |
| pharmacological measurements, 196 |
| suppositories, for neurogenic bowel dysfunction, 220 |
| surface electrical stimulation, for dysphagia, 57 |
| surgical external sphincterotomy, 212 |
| sustained attention, 13 |
| swallowing. See also dysphagia evaluation of, 53 |
| exercises, 54–6 |
| oesophageal phase, 52 |
| oral preparatory phase of, 52 |
| oral propulsive phase of, 52 |
| in Parkinson’s disease, 136 |
| pharyngeal phase, 52 |
| sensory-motor feedback loops in, 54 structures in, 52 |
| syncope, 193–4 |
| non-pharmacological measurements, 194–5 |
| pathophysiology of, 194 |
| situational, 194 |
| treatment of, 194 |
| systemic desensitization, 232 |
| tachycardia, 199 |
| Tai Chi, 113, 145–6 |
| task specific practice, 7 |
| TASC. See tool for assessment of suicide risk |
| TBI. See traumatic brain injury |
| tDCS. See transcranial direct current stimulation |
| team models |
| interdisciplinary, 5 |
| multidisciplinary, 5, 135 |
| neurorehabilitation, 5 |
| transcerebral, 5 |
| TENS. See transcutaneous electrical stimulation |
| Test-Retest reliability, 4 |
| therapy tasks, 42 |
| thermal stimulation, 54 |
| thyroid notch, 54–6 |
| thyroid stimulating hormone (TSH), 145 |
| tibial nerve stimulation, for LUT, 211 |
| Time Pressure Management (TPM), 13 |
| tizanidine, 126 |
| for spasticity, 123–4 |
| TMS. See transcranial magnetic stimulation |
| toileting, behavioural therapy and, 207 |
| tolterodine, for LUT, 210 |
| tool for assessment of suicide risk (TASR), 27 |
| Touchspeak, 47 |
| TPM. See Time Pressure Management |
| traditional exercise programs, 7 |
| tramadol, for neuropathic pain, 152–3 |
| transanal irrigation, 220 |
| transcranial direct current stimulation (tDCS), 5–6, 41, 43 |
| anodal, 35 |
| for aphasia, 44 |
| cathodal, 35, 44 |
| effects of, 44 |
| inhibitory, 44 |
| technique, 35 |
| for upper limb impairment, 79 |
| transcranial magnetic stimulation (TMS), 35, 43 |
| application of, 43–4 |
| repetitive, 5–6, 43–4 |
| for upper limb impairment, 79 |
| transcutaneous electrical stimulation (TENS), 146 |
| transdisciplinary team models, 5 |
| transient hypertensive surges, 198 |
| traumatic brain injury (TBI), 11–12, 14, 18, 90 |
| diagnoses after, 15–16 |
| headaches in, 18–19 |
| sleep and, 16–17 |
| treadmill training, 6, 113 |
| tricyclic antidepressants, 24–5, 62–3, 147–9 |
| for neuropathic pain, 150 |
| triggered voiding, 206–7 |
| trospium, for LUT, 210 |
| TRPV. See molecular drug targets |
| TSH. See thyroid stimulating hormone |
| unimodal training, 76–9 |
| unresponsive wakefulness syndrome (UWS), 30, 33 |
| visual pursuit and, 31 |
| unstimulated saliva, 61, 62 |
| upper limb impairment, 74 |
| associated disorders, 74 |
| bilateral arm training for, 79 |
| biofeedback for, 79 |
| Bobath approach for, 79 |
| brain-machine interfaces for, 81–2 |
upper limb impairment (cont.)
CIMT for, 79
complimentary interventions for, 79
FES for, 79
IADLs and, 76–9
intrathecal baclofen for, 81
mental practice for, 79
meta-analyses, 76
mirror therapy for, 79
motivation in treatment of, 75
music therapy for, 79
non-pharmacological treatments, 76–9
pharmacological treatment for, 80–1
reperfusion therapies for, 80–1
repetitive task training for, 79
robotists, 136
sensory interventions for, 79
stem cell therapy for, 81–2
strength training for, 79
stretching for, 79
stroke and, 74
surgical treatment for, 81–2
tDCS for, 79
TMS for, 79
treatment timing and setting, 74–6
Upper Motor Neuron syndrome, 111
urinary diversion, 212
urinary tract infection (UTI), 204
investigations, 205–6
treatment, 204–5
urologists, 136
UTI. See urinary tract infection
UWS. See unresponsive wakefulness syndrome
validity
construct, 4
content, 4
discriminant, 4
face, 4
VAS. See visual analogue scale
vascular endothelial growth factor (VEGF), 81
verbal contact, in challenging behaviour, 27
verbal de-escalation, in challenging behaviour, 28
verticalization to near standing position
contraindications for, 32–3
description of, 33
for DOC, 32–4
indication for, 32–3
rationale for, 32–3
review of evidence, 33–4
vertigo, 90, 105–7
phobic postural, 108
vestibular compensation, 100
vestibular hypofunction (BVH), 99–100
vestibular impairment, 90
incidence of, 90
in older adults, 90
pharmacotherapy, 91–2
surgery for, 91–2
treatment types, 91–2
vestibular migraine, 99
vestibular rehabilitation, 91, 100
adaptation exercises in, 94–6
customized, 94–100
dual-task activities and, 98
efficacy of, 99–100
exercises in, 95
factors affecting outcome of, 99
neurophysiological basis for, 93–4
postural alignment and, 95–6
sensory re-weighting and, 96–8
virtual reality-based techniques, 98–9
vestibulo-ocular reflex (VOR), 93–4, 114
VFSS. See videofluoroscopic swallowing study
vibrostimulation, 230
videofluoroscopic swallowing study (VFSS), 53
virtual reality, walking disorders and, 113
virtual reality-based techniques, vestibular rehabilitation, 98–9
visual analogue scale (VAS), 160
visual impairment. See also decreased visual acuity
driving and, 167
general participation and, 166–7
reading and, 166
visual pursuit, UWS and, 31
visual scanning training, 14
VOR. See vestibulo-ocular reflex
walking
aids, 113
analysis, 109–10
anxiety disorders and, 108
assessment, 110
balance and, 113
cerebellum in, 107
cortical areas in, 107
electromechanical training and, 113
fear and, 108
freezing, 137
gait cycle, 106
gait instability, 90
multi-linked musculoskeletal system in, 108
outcome measures, 110
phases of, 105
robotics and, 113
sensory rehabilitation and, 114
sensory systems in, 105–7
subcortical systems in, 107
task-related training, 113
walking disorders
cueing for, 112
dual task training for, 112
extrapyramidal signs in, 114–15
falls and, 115
FES for, 111
functional, 108
functional neurosurgery for, 115–16
high level, 107–8
management, 110
non-pharmacological treatment, 111
objective assessment of, 109–10
orthopaedic management of, 115
orthotic devices for, 112
pharmacological treatment of, 114
shoes for, 112
spasticity in, 114
splitting for, 111–12
stretching for, 111–12
subjective assessment of, 109
treatment types, 91–2
virtual reality and, 113
Waterlof scale, 182
Western Aphasia Battery, 44
WHO. See World Health Organization
Wilson’s disease, 62–3
working memory, 13
World Health Organisation (WHO), 1, 42
handicap scale, 4
wound debridement, for pressure ulcers, 183
wound dressings, for pressure ulcers, 183
wound healing, for pressure ulcers, 183
xerogenic medications, 62–3
xerostomia. See hyposalivation
yoga, 18
zolpidem for DOC, 37
evidence for, 37
indication for, 37
pharmacology of, 37
rationale, 37
side effects of, 37